SmithKline will pursue penciclovir switch "immediately" after Rx approval, CEO says.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE WILL PURSUE PENCICLOVIR SWITCH "IMMEDIATELY" AFTER Rx APPROVAL, CEO Jan Leschly told securities analysts at Bear Stearns' annual health care conference on Sept. 9-11 in New York City. Leschly predicted that the "real potential" for the topical cold sore medication is as an over-the-counter product. He noted that "25% of the population suffer from cold sores."